Correlation Between Uptake of 18F-FDG During PET/CT and Ki-67 Expression in Patients Newly Diagnosed With Multiple Myeloma Having Extramedullary Involvement. (19th July 2019)

• Record Type: Journal Article
• Authors: Li, Qian; Ma, Jing; Li, Han; Xu, Wengui; Cao, Zeng; Liu, Su; Chen, Lin; Gao, Shuang; Yan, Tinghui; Li, Dongying; Wang, Xue; Yue, Yuanfang; Zhao, Zhigang; Wang, Xiaofang; Yang, Hongliang; Zhao, Haifeng; Yu, Yong; Zhang, Yizhuo; Fan, Feiyue; Wang, Yafei
• Is Part Of: Technology in cancer research & treatment. Volume 18(2019)
• Publication Date: 2019-07-19
• Subjects: multiple myeloma -- extramedullary involvement -- Ki-67 -- PET-CT -- survival analysis; Oncology -- Periodicals; Cancer -- Diagnosis -- Periodicals; Cancer -- Treatment -- Technological innovations -- Periodicals; 616.994
• DOI: 10.1177/1533033819849067
• Languages: English
• ISSNs: 1533-0346

Abstract

The aim of this study was to evaluate the relationship of prognosis of patients with multiple myeloma having extramedullary involvement (EMM) with the 18 F- fluorodeoxyglucose(18F-FDG) maximum standardized uptake value and the expression of Ki-67 in biopsy samples. Sixty-five patients were newly diagnosed with multiple myeloma presenting with EMM at our hospital from January 2005 to January 2015. Of these 65 patients, 20 were enrolled in this study. Over the last decade, both the maximum standardized uptake value and Ki-67 expression in these extramedullary lesions significantly correlated with progression-free survival, respectively ( P = .039, P =.009). After combining—the maximum standardized uptake value and the Ki-67 expression as an integral—there was a significant correlation between both the overall survival ( P = .027) and progression-free survival ( P = .014). Patients have poor outcomes when EMM is detected at presentation. Both the maximum standardized uptake value and Ki-67 expression could aid in accurately evaluating EMM patient prognosis.